
Endogenous accumulation of alpha-synuclein in microglia-containing organoids; a new research breakthrough

OrganoTherapeutics Newsletter June 2025 ; Altered mtDNA dynamics and neurodegeneration in organoids

OrganoTherapeutics and molmir Announce Strategic Collaboration to Accelerate Neurodegenerative Disease Research

OrganoTherapeutics Newsletter - May 2025 ; Reproducibility of PD patient-specific midbrain organoid data

OrganoTherapeutics Joins Michael J. Fox Foundation’s LRRK2 Therapeutics Exchange with midbrain organoid systems

OrganoTherapeutics Newsletter - April 2025 ; Assessment and quantification of dopaminergic neurite fragmentation

Advancing reproducibility in organoid research: a breakthrough for midbrain models

FDA's shift from animal testing: unlocking the potential of midbrain organoids in drug development

OrganoTherapeutics Newsletter - March 2025 ; Neurofilament light release in organoids

OrganoTherapeutics Newsletter - February 2025 ; 3D tissue clearing for advanced imaging

Successful Project Collaboration with Animal Free Research UK: united for animal-free research

The move of OrganoTherapeutics: Welcome to our new fully-equipped laboratory spaces in Luxembourg

OrganoTherapeutics and mo:re join forces on the development of organoid culture automation

The Autonomous University of Barcelona and OrganoTherapeutics collaborate on Parkinson’s Disease therapeutics

New collaboration between OrganoTherapeutics and Juntendo for the transfer of PD patient samples
